Infections caused by ciprofloxacin-sensitive pathogens:
Infections of the Respiratory Tract: In the treatment of outpatients with pneumonia due to Pneumococcus, Ciprobay should not be used as a first choice of drug. Ciprobay can be regarded as an advisable treatment for pneumonias caused by Klebsiella, Enterobacter, Proteus, Pseudomonas, Haemophilus, Branhamella, Legionella and Staphylococcus.
Middle ear (otitis media) and paranasal sinuses (sinusitis), especially if these are caused by gram-negative organisms including Pseudomonas or by Staphylococcus.
Eyes; kidneys and/or the efferent urinary tract; genital organs, including gonorrhea; abdominal cavity (eg, bacterial infections of the gastrointestinal tract or of the biliary tract, peritonitis); skin and soft tissue; bones and joints; sepsis.
Infections or imminent risk of infection (prophylaxis) in the patients whose immune system have been weakened (eg, patients on immunosuppressants or in a state of neutropenia).
Selective intestinal decontamination in immunosuppressed patients.
Ciprobay acts bactericidally. The following pathogens can be regarded as sensitive: Escherichia coli, Shigella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia, Hafnia, Edwardsiella, Proteus (indole-positive and indole-negative), Providencia, Morganella, Yersinia; Vibrio, Aeromonas, Plesiomonas, Pasteurella, Haemophilus, Campylobacter, Pseudomonas, Legionella, Moraxella, Acinetobacter, Brucella; Staphylococcus, Listeria, Corynebacterium, Chlamydia.
The following show varying degrees of sensitivity: Neisseria, Gardnerella, Flavobacterium, Alcaligenes, Streptococcus agalactiae, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus pneumoniae, Viridans group streptococci, Mycoplasma hominis, Mycobacterium tuberculosis and Mycobacterium fortuitum.
The following are usually resistant: Enterococcus faecium, Ureaplasma urealyticum, Nocardia asteroides. Ciprobay is ineffective against Treponema pallidum.